GlassScriptPhysician profile
Michael Anthony Martucci
NPI 1942415369
$16,589.82
in general payments reported to CMS, 2019-2025
42 companies · $3,003 in 2025
The $3,003 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $1,395 · 2021: $2,169 · 2022: $2,449 · 2023: $3,362 · 2024: $2,690 · 2025: $3,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,914 · Education: $93.98 · Consulting Fee: $47.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,913.92 |
| Education | $93.98 |
| Consulting Fee | $47.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,465.77 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $2,256.00 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $1,772.98 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,295.55 | 2019-2025 | |
| Csl Behring | $961.23 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $877.51 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $801.67 | 2019-2025 | |
| Genentech USA, INC. | $579.43 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $525.75 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $381.05 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $370.64 | 2020-2025 | Ruconest |
| Optinose US, INC. | $351.05 | 2019-2023 | |
| Octapharma USA, INC. | $309.57 | 2019-2021 | |
| Kaleo, INC. | $272.89 | 2019-2024 | Auvi-Q |
| Amgen INC. | $245.96 | 2022-2025 | Tezspire |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Martucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.